 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Lung Cancer: Small Cell - Limited Disease
|
|
Amrubicin® and Paraplatin® Active and Tolerable in Elderly Patients with SCLC (10/22/2009)
Researchers from Japan have reported Amrubicin®, a new synthetic anthracycline, combined with Paraplatin® (carboplatin) resulted in an 89% overall response rate (ORR) in elderly patients with small cell lung cancer (SCLC). The details of this report appeared in an early online publication in the Annals of Oncology on October 13, 2009.
Thalidomide Doesn’t Benefit Patients with Small Cell Lung Cancer Treated with Etoposide and Carboplatin (7/24/2009)
Researchers from the U.K. have reported that treatment with a combination of thalidomide (Thalomid®) and chemotherapy did not improve survival among patients with small cell lung cancer, and resulted in a higher risk of blood clots than treatment with chemotherapy alone. The results of this study were published in the August issue of the Journal of the National Cancer Institute.
Non-Platinum Chemotherapy as Effective for SCLC (10/17/2008)
Researchers affiliated with the Cochrane Library have reported that chemotherapy regimens that do not contain platinum agents (Platinol and Paraplatin) appear to be just as effective as regimens that do contain platinum agents in the treatment of small cell lung cancer. These results were recently published in the Cochrane Database of Systematic Reviews.
Threefold Dose Intensity of ICE Does Not Improve Outcomes in Small Cell Lung Cancer (4/17/2008)
Researchers associated with the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation have reported that increasing the dose intensity of ICE (ifosfamide, carboplatin, and etoposide) by threefold by using peripheral blood stem cell support did not improve outcomes of patients with limited or extensive stage small cell lung cancer (SCLC). The details of this study appeared in an early online publication in the Journal of the National Cancer Institute on April 8, 2008.
PET Useful for Staging of Small Cell Lung Cancer (4/16/2008)
Researchers from West Virginia University have reported that positron emission tomography (PET) is useful for staging of small cell lung cancer (SCLC). The details of this study appeared in the January 2008 issue of Clinical Lung Cancer.
Oral and Intravenous Hycamtin® Equally Effective for Small Cell Lung Cancer (5/24/2007)
Researchers involved in an international study have confirmed that the oral form of Hycamtin (topotecan) is as effective as the intravenous form for the second line palliative treatment of small cell lung cancer (SCLC). The details of this randomized trial appeared in the May 20, 2007 issue of the Journal of Clinical Oncology.
Dose-Intensive Chemotherapy with Stem Cell and Neupogen® Support Improves Survival in SCLC (2/5/2007)
A randomized phase III study that intensified doses of ICE (ifosfamide, carboplatin, and etoposide) administered with autologous stem cell and Neupogen (filgrastim) support improves median survival compared to standard doses of ICE for the treatment of small cell lung cancer (SCLC).
Calypso® 4D Localization System May Improve Efficacy of External Beam Radiotherapy (12/1/2006)
At the 2006 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in November there were 10 abstracts presented that describe a new system for measuring and monitoring organ motion in real time during external beam radiotherapy (EBRT).
Concurrent Chemotherapy, Twice-Daily Radiation and Consolidation Chemotherapy Promising for Limited Small Cell Lung Cancer (11/27/2006)
Researchers from Japan have reported that concurrent twice-daily radiotherapy and standard VePesid® (etoposide) plus Platinol® (cisplatin) followed by consolidation with Camptosar® (irinotecan) plus Platinol may improve outcomes of patients with limited-disease small cell lung cancer (LD-SCLC).
Paraplatin®, Camptosar® Supported by Neupogen® Well Tolerated in Elderly with Small Cell Lung Cancer (8/4/2006)
Researchers from Japan have reported that a regimen of Paraplatin (carboplatin) and Camptosar (irinotecan) supported by Neupogen was effective and well tolerated in elderly patients with small cell lung cancer (SCLC).
Shorter Duration of Treatment Improves Survival with Small-Cell Lung Cancer (3/13/2006)
Researchers from Belgium have reported that a shorter treatment interval is associated with an improved survival of patients with limited-disease small-cell lung cancer (SCLC).
Neupogen® Plus Antibiotics Decrease Febrile Neutropenia in Small Cell Lung Cancer (11/8/2005)
Researchers from the Netherlands have reported that the addition of Neupogen (granulocyte-colony stimulating factor) to prophylactic antibiotics decreases febrile neutropenia in patients with small cell lung cancer (SCLC) undergoing intensive sequential chemotherapy.
Concurrent Chemotherapy and Radiation Therapy Superior to Sequential Administration for Patients with Limited-Stage Small Cell lung Cancer (SCLC) (7/19/2002)
Small-cell lung cancer (SCLC) responds well to both chemotherapy and radiation therapy and these modalities are usually combined for the treatment of limited- stage disease. Limited-stage SCLC is confined to one side of the chest and is potentially curable. However, the optimal combination of radiation therapy and chemotherapy is yet to be determined. One of the more effective drug combinations for the treatment of SCLC is cisplatin and etoposide. In the July 15, 2002 issue of the
Journal of Clinical Oncology, Japanese researchers reported that survival of patients was better if radiation was delivered with chemotherapy rather than sequentially.
|
|
Patient Home
